Pelareorep

Phase 2Biologic

OOncolytics Biotech

Pelareorep is one of 130 biologic programs targeting Intestinal Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

129

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intestinal CancerActive, not recruiting

Breast CancerActive, not recruiting

Colorectal CancerActive, not recruiting

Multiple MyelomaActive, not recruiting

Intestinal CancerPhase 1/Phase 2

Active, not recruiting

Breast CancerPhase 1

Active, not recruiting

Colorectal CancerPhase 2

Active, not recruiting

Multiple MyelomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Halaven

Eisai

Preclinical

38 2

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 3

Pelareorep

OOncolytics Biotech

Phase 2

4 4

Megace

Bristol-Myers Squibb

Preclinical

4 5

Lexiscan

Astellas

Preclinical

1 6

Adenocard

Astellas

Preclinical

1 7

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 8

Spravato

WWim Janssens

Preclinical

2 9

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 10

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1/2Active, not recruiting

Multiple Myeloma

NCT05514990

Q4 2028

Phase 1/2Recruiting

Intestinal Cancer

NCT07280377

Q2 2030

Phase 2Not yet recruiting

Colorectal Cancer

NCT07446322

Clinical

Trials by Indication[1]

Breast Cancer4 trials

INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study

Active, not recruiting·MMridula George, MD·Phase 2·NCT04445844·25 enrolled

A Window-of-opportunity Study of Pelareorep in Early Breast Cancer

Terminated·OOncolytics Biotech·Phase 1·NCT04102618·26 enrolled

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

Active, not recruiting·OOncolytics Biotech·Phase 2·NCT04215146·48 enrolled

Show 1 more trial

Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer

Completed·AAdlai Nortye Biopharma Co., Ltd.·Phase 1·NCT05519059·15 enrolled

Multiple Myeloma3 trials

Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT02101944·12 enrolled

Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma

Completed·EEmory University·Phase 1·NCT03605719·23 enrolled

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

Active, not recruiting·UUniversity of Southern California·Phase 1/2·NCT05514990·10 enrolled

Primary Peritoneal Cancer1 trial

Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01199263·108 enrolled

Colorectal Cancer1 trial

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

Not yet recruiting·OOncolytics Biotech·Phase 2·NCT07446322·60 enrolled

Intestinal Cancer1 trial

A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab

Recruiting·OOncolytics Biotech·Phase 1/2·NCT07280377·122 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Pelareorep. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pelareorep compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pelareorep. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Oncolytics Biotech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: OOncolytics Biotech

Pelareorep

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2028

Q2 2030

Trials by Indication[1]

Breast Cancer4 trials

Multiple Myeloma3 trials

Primary Peritoneal Cancer1 trial

Colorectal Cancer1 trial

Intestinal Cancer1 trial

References

Drug Info

Quick Facts

Related News